Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.
‘Inferior efficacy’ leads to premature end of PhIII for Bayer’s next-gen blood thinner asundexian
Bayer is bringing a Phase III trial for its blood thinner asundexian to an early end after the drug showed “inferior efficacy” against the control